1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Diurnal Adrenal Franchise Takes Shape With Alkindi Launch

 
• By Kevin Grogan

With the launch in Germany of Alkindi, Diurnal has kickstarted its plan of offering therapies that treat patients with cortisol deficiency diseases from birth right the way through to old age and the market is potentially a very lucrative one.

SC1805_German Flag_401163508_1200.jpg
German launch should be first of many for Diurnal • Source: Shutterstock

Very few UK biotechs have taken a product from concept to commercialization under their own steam but Diurnal has managed it, having launched Alkindi (immediate-release hydrocortisone) earlier this month in Germany as replacement therapy for adrenal insufficiency (AI) in infants.

It has been "a long hard slog" for the company which was founded as a spin-out from the University of Sheffield back in 2004, CEO Martin Whitaker told Scrip in an interview. However, Diurnal has moved quickly since getting European marketing authorization for Alkindi in February 2018, with the German launch being announced May 15

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.